<DOC>
	<DOCNO>NCT01520389</DOCNO>
	<brief_summary>This study Phase 1 pharmacologic open-labeled dose-escalation trial use `` 3+3 '' design , evaluate MM-151 vary dose level frequency , subsequently combination irinotecan .</brief_summary>
	<brief_title>Safety Study Drug MM-151 Patients With Advanced Solid Tumors Resisting Ordinary Treatment</brief_title>
	<detailed_description>This study Phase 1 pharmacologic open-labeled dose-escalation trial use `` 3+3 '' design explore weekly , bi-weekly , tri-weekly dosing schedule . Successive MM-151 monotherapy cohort three patient treat escalate dos maximum tolerate dose identify , subsequently combination irinotecan . The study consist three part follow : MM-151 monotherapy dose escalation ( Part 1 ) ; MM-151 monotherapy expansion cohort cetuximab-refractory colorectal cancer ( Part 2 ) ; MM-151 + irinotecan dose escalation ( Part 3 ) . It expect approximately 4 study site participate .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients must histologically cytologically confirm advanced malignant solid tumor recur progress follow standard therapy , respond standard therapy , standard therapy , candidate standard therapy Patients must &gt; 18 year age Patients legal representative must able understand sign inform consent form Patients must evaluable measurable tumor ( ) Patients must recover effect prior surgery , radiotherapy antineoplastic therapy . Up CTCAE Grade 1 acceptable patient know peripheral neuropathy Women childbearing potential well fertile men partner must agree abstain sexual intercourse use effective form contraception study 90 day follow last dose MM151 ( effective form contraception oral contraceptive double barrier method ) Patients potentially curative antineoplastic therapy available Patients pregnant lactate Patients active infection unexplained fever &gt; 38.5Â°C screen visit first schedule day dose . ( At discretion investigator , patient tumor fever may enrol . ) Patients untreated and/or symptomatic CNS malignancy ( primary metastatic ) ; patient CNS metastases undergone surgery radiotherapy , whose disease stable , stable dose corticosteroid least 2 week prior first schedule day dose eligible trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>oncology</keyword>
	<keyword>Phase I</keyword>
	<keyword>EGFR</keyword>
	<keyword>EGF receptor ( ErbB1 )</keyword>
	<keyword>irinotecan</keyword>
</DOC>